Alzheimer's disease (AD) is characterized by both amyloid and Tau pathologies. The amyloid component and altered cholesterol metabolism are closely linked, but the relationship between Tau pathology and cholesterol is currently unclear. Brain cholesterol is synthesized in situ and cannot cross the blood-brain barrier: to be exported from the central nervous system into the blood circuit, excess cholesterol must be converted to 24S-hydroxycholesterol by the cholesterol 24-hydroxylase encoded by the CYP46A1 gene. In AD patients, the concentration of 24S-hydroxycholesterol in the plasma and the cerebrospinal fluid are lower than in healthy controls. The THY-Tau22 mouse is a model of AD-like Tau pathology without amyloid pathology. We used this model to investigate the potential association between Tau pathology and CYP46A1 modulation. The amounts of CYP46A1 and 24S-hydroxycholesterol in the hippocampus were lower in THY-Tau22 than control mice. We used an adenoassociated virus (AAV) gene transfer strategy to increase CYP46A1 expression in order to investigate the consequences on THY-Tau22 mouse phenotype. Injection of the AAV-CYP46A1 vector into the hippocampus of THY-Tau22 mice led to CYP46A1 and 24S-hydroxycholesterol content normalization. The cognitive deficits, impaired long-term depression and spine defects that characterize the THY-Tau22 model were completely rescued, whereas Tau hyperphosphorylation and associated gliosis were unaffected. These results argue for a causal link between CYP46A1 protein content and memory impairments that result from Tau pathology. Therefore, CYP46A1 may be a relevant therapeutic target for Tauopathies and especially for AD.
Introduction
Alzheimer's disease (AD), the most common form of dementia, is characterized by two main pathological features: senile plaques and neurofibrillary tangles (NFT) (1) . Senile plaques are composed of amyloid peptide deposits and NFT result from the accumulation and aggregation of hyperphosphorylated Tau proteins. Tau aggregates characterize a group of diseases referred to as Tauopathies (2) . Tau hyperphosphorylation is associated with cognitive alterations in several types of dementia (3) . Notably, in human AD brains, the progressive spatiotemporal progression of Tau pathology from the hippocampus to isocortical regions correlates with cognitive impairments (4-7), implicating it in memory deficits. Several experimental models exhibiting Tau hyperphosphorylation and/or aggregation support this link (8) (9) (10) (11) (12) (13) .
Dysregulation of brain cholesterol homeostasis is observed in AD. The presence of the apolipoprotein E ε4 allele, the brain's principal cholesterol-carrier protein, is the main genetic risk factor for sporadic forms of AD (14) (15) (16) (17) . In adults, brain cholesterol is produced in situ and is not able to cross the blood-brain barrier: it is mostly exported as 24S-hydroxycholesterol, produced by cholesterol 24-hydroxylase (CYP46A1) (18) expressed only in neurons (19) .
Brain cholesterol dyshomeostasis appears to be linked to AD. Increased cholesterol levels have been observed in vulnerable brain regions (20, 21) , and in particular in tangle-bearing neurons of AD patients (22) . Patients with advanced AD or dementia exhibit reduced 24S-hydroxycholesterol levels in both plasma (23) (24) (25) (26) and cerebrospinal fluid (CSF) (27) . Furthermore, Tau phosphorylation and 24S-hydroxycholesterol concentrations in the CSF correlate (26) , suggesting a relationship between Tau pathology and 24S-hydroxycholesterol.
We report that hippocampal CYP46A1 protein and 24S-hydroxycholesterol levels were reduced in a mouse model of AD-like Tau neuropathology (8) . Normalizing 24S-hydroxycholesterol in the hippocampus of Tau mice restored memory and synaptic impairments associated with the Tauopathy, consistent with the CYP46A1 deficit having a direct role in Tau-related physiopathology.
Results
Hippocampal CYP46A1 protein concentration is reduced in mouse models of Tauopathy CYP46A1 protein was assayed in the hippocampus of THY-Tau22 mice which exhibit progressive neuron-specific AD-like Tau pathology associated with behavioral impairments (13) . There was significantly less (P = 0.002) CYP46A1 protein in the hippocampus of THY-Tau22 than control WT mice ( Fig. 1A and B) . The total free cholesterol content in the hippocampus of THY-Tau22 mice was normal (NS; data not shown), but the 24S-hydroxycholesterol content was significantly lower than in WT (P = 0.05; Fig. 1D ). Reduced hippocampal CYP46A1 concentration was confirmed in another Tau transgenic mouse model (THY-Tau30 mice (28) ; Fig. 1A and C) ruling out a potential effect of the transgene insertion site. These two models did not exhibit neuronal loss (13, 28 ).
CYP46A1 overexpression restored the level of 24S-hydroxycholesterol and activated the cholesterol synthesis pathway in the hippocampus of THY-Tau22 mice Adeno-associated virus vectors encoding the human CYP46A1 cDNA (AAV-CYP) or a mutated inactive form of the enzyme (AAV-Ctrl) were bilaterally injected into the hippocampus of 3.5-month-old THY-Tau22 and WT littermates. Tau pathology and related disturbances are minor at this age in this model.
Expression of vector-encoded CYP46A1 (29) was restricted to hippocampal neurons ( Fig. 2A-F) . The hippocampal concentration of CYP46A1 was significantly increased in the hippocampus of THY-Tau22 and WT mice after injection of the AAV-CYP vector in comparison to non-injected controls (P = 0.04) (Fig. 2G) . Subsequently, hippocampal levels of 24S-hydroxycholesterol were increased in both THY-Tau22 and WT mice (P = 0.04). The levels of 24S-hydroxycholesterol in THY-Tau22 AAV-CYP mice were thus similar to those in WT AAV-Ctrl animals (Fig. 2H) .
The changes in 24S-hydroxycholesterol concentration following AAV-CYP injection were not associated with increased Fig. S1 ). Total cholesterol (Genotype effect: P = 0.48; Treatment effect: P = 0.30; no interaction; Fig. 2I ) and cholesterol in lipid rafts (Genotype effect: P = 0.77; Treatment effect: P = 0.95; no interaction; Fig. 2J and Supplementary Material, Fig. S2 ) contents were unchanged. By contrast, expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), the ratecontrolling enzyme of cholesterol synthesis, was significantly increased (Treatment effect: P = 0.002; Supplementary Material, Figs. S3 and S4A).
We tested for effects of CYP46A1 overexpression on the expression of the 22 enzymes implicated in cholesterol synthesis in WT and THY-Tau22 mice using microarray analysis. Genes of the mevalonate and the lanosterol pathways were significantly more strongly expressed after injection of AAV-CYP in THYTau22 mice (Supplementary Material, Figs. S3 and S4).
CYP46A1 overexpression prevented memory defects in THY-Tau22 mice
Short-and long-term spatial memories were independently studied using Y-maze and Morris Water Maze (MWM) tasks, respectively. Within-subject analysis of variance (ANOVA) on Y maze performances showed a genotype (THY-Tau22 versus WT) by treatment (CYP46A1 overexpression versus control) interaction effect (distance: P = 0.03; entries: P = 0.02). As expected (30) , THY-Tau22 AAV-Ctrl mice traveled less distance (P = 0.01) and entered less (P = 0.03) in the new arm than WT AAV-Ctrl animals. In contrast, THY-Tau22 AAV-CYP mice displayed an efficient (Fig. 3A) . We checked that CYP46A1 overexpression had no effect on motor abilities in open-field and Y-maze tasks (Supplementary Material, Fig. S5 ).
One-way ANOVA with repeated measure on the latency to find the platform during the learning phase of the MWM task showed a significant group effect (P < 0.01) and time effect (P < 0.001) (Fig. 3B) . The latency to reach the hidden platform was longer for THY-Tau22 AAV-Ctrl mice than WT mice (P = 0.02). Injection of the AAV-CYP vector did not improve performance of WT mice (NS). Conversely, latency to find the platform was significantly reduced in THYTau22 mice following injection of AAV-CYP (P = 0.003 versus THYTau22 AAV-Ctrl animals) and was identical to that for WT mice (NS) (Fig. 3B) . The probe test was performed 72 h after the last training trial. Analysis of variance of the percentage of time in the target quadrant showed a significant group effect (P = 0.03; Fig. 3C and D). THY-Tau22 AAV-Ctrl mice spent less time than the three other groups in the target quadrant (P = 0.004), whereas THY-Tau22 AAV-CYP mice and WT mice had similar performances (NS) ( Fig. 3C and D) . Thus, the injection of the AAV-CYP vector, which had no effect on spatial memory performances in WT animals, strongly improved THY-Tau22 performance to be similar to WT.
CYP46A1 overexpression did not affect Tau phosphorylation and gliosis in THY-Tau22 mice
Tau pathology has been associated with spatial memory disturbances in THY-Tau22 mice. We therefore investigated the phosphorylation of Tau in these Tau transgenic mice (31) (32) (33) . Immunohistochemistry (IHC) failed to evidence differences in Tau hyperphosphorylation (AT8: P = 0.72; AT270: P = 0.47) or abnormal phosphorylation (AT100: P = 0.86) between THY-Tau22 AAV-CYP and THY-Tau22 AAV-Ctrl mice ( Fig. 4A and D) . Two-dimensional electrophoresis (30, 33) failed to evidence differences in overall Tau phosphorylation between THY-Tau22 mice injected with AAV-CYP or AAV-Ctrl vectors (Fig. 4B ). We also studied the level of several phospho-epitopes using mono-dimensional electrophoresis (Supplementary Material, Fig. S6 ). We did not observe change at pThr181, pSer199, pSer214, pSer262, pSer396, pSer404 (Supplementary Material, Fig. S6 ) in THY-Tau22 mice overexpressing CYP46A1. Total Tau level remained also the same regardless the group. Finally, we tested whether CYP46A1 overexpression affected Tau aggregation: the amounts of sarkosyl-insoluble Tau were similar in both AAV-injected animals (P > 0.05; Fig. 4C ). Tau pathology can drive gliosis (31,34), so we compared astrocytosis (GFAP-positive staining) and microgliosis (Iba1-positive staining) in the hippocampus between THY-Tau22 mice injected with the AAV-CYP or AAV-Ctrl vector. There was no difference between the groups (GFAP: Genotype effect: P = 0.0006, Treatment effect: NS, no interaction; Iba1: Genotype effect: P = 0.03, Treatment effect: NS, no interaction) ( Fig. 4A and D) .
CYP46A1 overexpression improved synaptic processes underlying memory in THY-Tau22 mice
To understand the cellular mechanisms involved in memory rescue, we evaluated the functionality of neurons. We studied only three groups [WT AAV-Ctrl mice (as controls) and THY-Tau22 AAV-Ctrl and THY-Tau22 AAV-CYP mice], as WT AAV-CYP animals did not display better memory performances than WT AAV-Ctrl mice in the tests used. Basal synaptic transmission and Ca 2+ -dependent presynaptic glutamate release were similar in the three groups. The plasticity induced by theta-burst stimulation (TBS) was indistinguishable in WT, THY-Tau22 AAV-Ctrl and THYTau22 AAV-CYP mice (P = 0.17) (Supplementary Material, Fig. S7 ).
In sharp contrast, long-term depression (LTD) induced by lowfrequency stimulation was significantly different between the three groups (P = 0.02). Long-term depression in slices from WT mice (75.4 ± 5.6% of the baseline) was almost completely abolished in THY-Tau22 AAV-Ctrl mice (P = 0.008), confirming previous results (13, 30) . Following injection of the AAV-CYP vector into THY-Tau22 mice, LTD was rescued to a similar level to that in WT animals (THY-Tau22 + AAV-CYP versus WT + AAV-Ctrl: NS; THY-Tau22 + AAV-CYP versus THY-Tau22 + AAV-Ctrl: P < 0.05) (Fig. 5A and B) .
CYP46A1 overexpression rescued dendritic length and spine density in THY-Tau22 mice
We studied dendritic length and spine density in the hippocampal CA1 region of THY-Tau22 mice. Secondary dendrites in the stratum radiatum were significantly shorter in THY-Tau22 mice (28.8 ± 1.3 µm) than WT mice (37.1 ± 1.5 µm) (P = 0.0001). This difference was completely abolished by CYP46A1 overexpression (35.5 ± 1.5 µm; NS and P = 0.002 versus WT and THY-Tau22 AAVCtrl mice, respectively) ( Fig. 5C and D) . CA1 spine density was analyzed both in the stratum oriens (basal dendrites) and in the stratum radiatum ( proximal apical dendrites). The spine density was lower for neurons in THY-Tau22 AAV-Ctrl mice than in WT animals (basal dendrites: P < 0.0001; apical dendrites: P = 0.01). CYP46A1 overexpression significantly increased the spine density in THY-Tau22 mice (basal dendrites: P < 0.0001; apical dendrites: P = 0.005) to values similar to those in WT mice (basal dendrites: NS; apical dendrites: NS) (Fig. 5E and F) .
CYP46A1 overexpression improved molecular processes underlying memory in THY-Tau22 mice
We analyzed the expression of nine immediate early genes (IEGs), 30 min after Y maze stimulation: the values for WT AAVCtrl mice were established as the basal expression (Fig. 5G) . Expression of Arc, Egr1 (also known as Zif268), 2 and 4, Fos and Fosb was weaker in THY-Tau22 AAV-Ctrl mice than WT mice (one sample t-test with 0 for hypothetical value: P = 0.04; P = 0.004; P < 0.0001; P = 0.01; P = 0.008; P = 0.02; respectively). The expressions of each of Arc, Egr1, 2 and 4, Fos and Fosb in THY-Tau22 AAV-CYP mice were similar to those in the WT, whereas Homer1, Jun and Junb expressions were unaffected (Fig. 5G) .
Discussion
The present study demonstrates, for the first time, the close relationship between Tau neuropathology, its consequences upon cognitive and synaptic functions and CYP46A1, a key enzyme of cholesterol metabolism in the brain. We specifically demonstrate that Tau pathology is associated with reduced CYP46A1 hippocampal level in Tau transgenic mice and its restoration leads to the normalization of memory abilities, neuronal morphology, neuronal function and synaptic defects. These observations strongly implicate CYP46A1 defects in the synaptic and memory dysfunctions of Tau pathology.
There is compelling experimental data of a direct link between CYP46A1 expression, processes of learning and memory and cognitive abilities. Transgenic CYP46A1 knock out (KO) mice exhibit severe memory deficits (35) , and old transgenic animals overexpressing CYP46A1 exhibit improved performances (36) . Therefore, the reduced CYP46A1 and 24S-hydroxycholesterol levels in Tau transgenic mice may be responsible for the memory impairments associated with Tau pathology. To investigate this possibility, we increased CYP46A1 expression in the hippocampus of THY-Tau22 mice. This led to 24S-hydroxycholesterol normalization, confirming that the CYP46A1 protein was produced and functional. Importantly, overexpression of CYP46A1 in a restricted region of the murine hippocampus was sufficient to normalize the overall level of diffusible hippocampal 24S-hydroxycholesterol. Restoring hippocampal CYP46A1 fully restored the memory abilities of THY-Tau22 mice. Memory rescue associated with CYP46A1 overexpression has previously been described in an amyloid model of AD (29) and in a context of physiological aging (36) .
The observation that CYP46A1-induced memory rescue was not associated with normalization of hyper/abnormal Tau phosphorylation is puzzling. This result is reinforced by the lack of inflammatory changes seen in CYP46A1 overexpressing mice. Indeed, in THY-Tau22 mice, Tau pathology has been associated to innate inflammatory changes that were found reduced by treatments reducing Tau pathology (30, 31, 34) . Our observations thus suggest that CYP46A1 defect is probably downstream from Tau phosphorylation and/or aggregation and that this impairment could be implicated in the detrimental effect of Tau pathology on memory and synaptic plasticity. This hypothesis is in accordance with previous works demonstrating memory improvements without Tau pathology changes in mouse Tauopathy models (37) (38) (39) . Mechanisms explaining the improved memory abilities of CYP46A1 overexpressing THY-Tau22 mice remain however unknown so far. In THY-Tau22 mice, behavioral impairments have been particularly associated to several pathways such as cholinergic neuron degeneration (40) , BDNF unresponsiveness and NMDA receptor dysfunction (8) . Interestingly, cholinergic neurons from NPC1-deficient mice, characterized cholesterol overload in neurons, have been reported to exhibit disrupted neuronal morphology, suggesting early signs of neurodegeneration (41) . Moreover, neuronal response to BDNF was suggested to depend upon lipid rafts (42) . Finally, 24S-hydroxycholesterol has been recently shown to act as a very potent and selective positive allosteric modulator of NMDARs (43) . It remains thus possible that CYP46A1 overexpression modulates one of the above-mentioned mechanisms disrupted by Tau and instrumentally involved in memory deficits. Memory improvement in THYTau22 mice could also be a direct consequence of the restoration of hippocampal 24S-hydroxycholesterol levels. 24S-hydroxycholesterol induces an APOE-mediated efflux of cholesterol from astrocytes in vitro via an LXR-controlled pathway (44) . Numerous studies have shown that LXR agonists improve memory in various mouse models (45) (46) (47) (48) . However, CYP46A1 overexpression in the brain, either in a transgenic CYP46A1 mouse (49) or following AAV-CYP injection in both amyloid (29) and Tau (the present study) models, does not modify expression of LXR target genes. These observations suggest that memory restoration in THYTau22 mice are not mediated by the LXR pathway.
Consistent with previous work (49), hippocampal CYP46A1 restoration in THY-Tau22 mice was accompanied by activation of both mevalonate and lanosterol pathways, both involved in cholesterol biosynthesis; however, the total cholesterol amount was unaffected. Cholesterol turnover via cholesterol 24-hydroxylase ensures the activation of the mevalonate pathway and the constant synthesis of adequate levels of isoprenoid products, such as geranylgeraniol, that are essential for learning (35, 50) . The link between the mevalonate pathway and memory abilities (36) , and the restoration of the mevalonate pathway following CYP46A1 overexpression in THY-Tau22 mice, may explain memory improvement observed in THY-Tau22 mice after AAV-CYP injection.
In AD brains, NFT development is associated with progressive loss of dendritic spines and with dendrite atrophy (51) . Spine and dendrite alterations have been linked to Tau pathology in transgenic models (9, 52) . In our THY-Tau22 mouse model, in addition to the impaired hippocampal LTD previously described (13), dendrite length and spine density of CA1 pyramidal neurons were significantly lower than in WT. We also replicated impaired hippocampal expression of the IEG Arc described in two other transgenic Tau mouse models (53, 54) . Behaviorally induced hippocampal expression of several IEGs (Arc, Egr1, 2 and 4, Fos and Fosb), known to be essential during memory processing (55, 56) , was significantly altered in THY-Tau22 mice. Importantly, all these memory-related processes were restored following normalization of hippocampal CYP46A1 expression. Our various findings suggest that the CYP46A1 deficit in THY-Tau22 mice is instrumental for memory impairments resulting from a reduction of IEG expression following behavioral stimulation, spine architecture and neuron connectivity. This view is in accordance with the synaptic tuning by CYP46A1 level described in transgenic mice overexpressing this enzyme (36) . In addition to its role as a regulator of cholesterol synthesis pathway, CYP46A1 may therefore control or modulate, either directly or indirectly, crucial elements of neuron function.
Our study suggests that the memory impairment and synaptic dysfunction observed in THY-Tau22 mice is a consequence of a CYP46A1 deficit caused by the Tau pathology. Further studies are needed to elucidate the link between Tau pathology and CYP46A1 concentration and the mechanisms by which CYP46A1 acts on synaptic function. Decreased 24S-hydroxycholesterol production and increased cholesterol in tangle-bearing neurons in AD patient brains suggest that our observations are relevant to human pathology. Thus, restoring CYP46A1 to the brain could be a relevant therapeutic strategy for Tauopathies including AD.
Methods and Materials
AAV plasmid design and vector production Vector production has been described elsewhere (29) . PAAV5-PGK-HAhCYPwt-WPRE-BGHpolyA and PAAV5-PGK-HAhCYPmut-WPRE-BGHpolyA plasmids contain AAV 5 inverted terminal repeat sequences, murine phosphoglycerate kinase promoter, the human wild-type (WT) or mutated (A1309C mutation) CYP46A1 gene, respectively, human influenza hemagglutinin (HA) tag, woodchuck hepatitis virus post-transcriptional regulatory element and bovine growth hormone poly A sequence. These plasmids were used to generate AAV5/5-PGK-HACYP46A1 (referred to as AAV-CYP) and AAV5/5-PGK-HACYP46A1mut (referred to as AAVCtrl) vectors (P. Moullier, INSERM UMR 1089, Nantes, France). A mutated human CYP46A1 transgene coding for an inactive enzyme was used as a control.
Animals
THY-Tau22 mice express, in neurons of both cortex and hippocampus, the 412 amino acid 4-repeat isoform of human Tau (1N4R) mutated at sites G272V and P301S (13, 57, 58) . All transgenic (Tg) mice used in this study were heterozygous. Non-Tg littermates (C57BL6/J background) were used as wild-type controls (referred to as WT). THY-Tau22 mice display Tau pathology (defined as Tau hyperphosphorylation and pathological Tau phosphorylation, Tau filaments and neurofibrillary tangle-like inclusions) but no motor dysfunction. Supplementary expression of the same mutated Tau in the spinal cord in THY-Tau30 mice leads to a more severe phenotype with motor impairment and short life span that preclude the possibility of performing memory tests (28) in comparison to THY-Tau22 mice (58) . All experiments were conducted in accordance with the ethical standards of French and European regulations (Directive 2010/63/EU). 
Stereotactic injections of AAVs

Brain samples
To study Tau phosphorylation, mice were quickly killed without anesthesia (cervical dislocation) to avoid any aberrant Tau hyperphosphorylation (11, 59) . For the other experiments, mice were anesthetized and then transcardially perfused with Phosphate Buffered Saline 0.1 M before brain extraction. For lipidomic analyses, biochemistry, molecular biology and microarrays, the hippocampus of one hemisphere was dissected and quickly frozen in liquid nitrogen. For IHC, one hemisphere was removed, post-fixed in 4% paraformaldehyde and then transferred to cryoprotective solution (sucrose 30%). Sections 40 µm thick were cut with a freezing microtome (Leica Microsystems, Wetzlar, Germany).
Most of our experiments were performed at 9 months of age. Some experiments (Y-maze and genomic studies) were performed at 6 months of age (see below).
Cholesterol and 24S-hydroxycholesterol measurements
Lipids including cholesterol and 24S-hydroxycholesterol were extracted from frozen hippocampi as previously described (60) . Cholesterol and 24S-hydroxycholesterol were derivatized and analyzed by UPLC-ESI-HRMS as previously described (61) .
Cholesterol in lipid rafts
We adapted Butchbach's protocol (62) as follows: mouse hippocampi were homogenized with 250 µl ice-cold TBS buffer (10 m Trizma Base pH 8, 150 m NaCl and protease and phosphatase inhibitors) using a Dounce homogenizer. The homogenates (diluted to 3 mg/ml protein) were then incubated with 1% Brij-58 for 60 min at 4°C, after which sucrose was added to the samples to give a final concentration of 42.5%. A total of 1 ml of each sample was overlaid with 2.4 ml of 35% sucrose followed by 1.6 ml of 5% sucrose and centrifuged for 18 h at 149 000 g at 4°C using a MLS50 rotor (Beckman Coulter). Ten 500 µl fractions were taken from each sample. Lipid raft fractions were identified by Western Blot analysis using the flotillin-1 marker (BD Biosciences). Cholesterol and protein levels were measured in each of the fractions (Cholesterol: Amplex ® Red Cholesterol Assay Kit, Invitrogen™; Protein: BCA Protein Assay, Thermo Scientific).
Western blotting
Frozen hippocampi from 9-month-old mice were homogenized in a lysis buffer (TBS, NaCl 150 m, Triton 1%) containing phosphatase and protease inhibitors (Roche; Thermo Scientific ® ), then centrifuged (4 min, 4500 g, 4°C). Supernatants were collected and the protein content quantified (BCA Protein Assay, Thermo Scientific). Samples were resolved by SDS PAGE, and the proteins transferred to nitrocellulose membranes. The membranes were incubated with an anti-CYP46A1 antibody (1/500; Millipore, Billerica, MA) overnight at 4°C. This anti-CYP46A1 antibody recognizes both human and mouse CYP46A1 protein and cannot distinguish the active human CYP46A1 from the mutated inactive form. Anti-GAPDH antibody (1/1000; Abcam) was used as a loading control. For Tau biochemical experiments, tissue was homogenized in 200 μl Tris buffer ( pH 7.4) containing 10% sucrose and protease inhibitors (Complete; Roche Diagnostics GmbH), sonicated, and kept at −80°C until use as previously described (30) (Laurent Mol Psy). Protein amounts were evaluated using the BCA assay (Pierce). Tau antibodies included anti-pThr181 (AT270; Pierce); pS262, pSer396, pSer404 (Invitrogen); pSer214 (Sigma); pSer199 (home-made); total Tau Cter (home-made antibody recognizing the 11 amino-acids in C-terminal part of Tau).
ELISA AT270
Phospho-Tau ( pThr181) was quantified using the Innotest Phospho-Tau kit (Fujirebio Europe, Gent, Belgium) according to the supplier's instructions.
2D Electrophoresis
Two-dimensional electrophoresis experiments were performed as previously described (33) . Membranes were incubated with total Tau antibody (Cter).
Sarkosyl-soluble/insoluble proteins
Hippocampi of 9-month-old mice were prepared as previously described (30) .
Real-time quantitative PCR (RT-qPCR)
Real-time quantitative (RT-q)PCR using the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) was described in detail elsewhere (63) . The RNABle ® Kit (Eurobio, Courtaboeuf, France) was used to extract total RNA from frozen individual hippocampi of 9-month-old mice. Transcripts of the TBP gene encoding the TATA box-binding protein were quantified as an endogenous RNA control. The nucleotide sequences of the primers are reported in Supplementary Material, Table S1 .
Immunohistochemistry and immunofluorescence (IF)
Slices from 9-month-old mice were washed with PBS 0.1 M and permeabilized with PBS-Triton 0.20%. For IHC, endogenous peroxidase was quenched with PBS containing 3% H 2 O 2 for 5 min. Slices were saturated with 5% normal goat serum and incubated overnight at 4°C with diluted specific primary antibodies (Supplementary Material, Table S2 ). For IHC, streptavidin, horseradish peroxidase conjugate and 3,3′-diaminobenzidine were used according to the manufacturer's manual (Vector ® DAB, Vector
Laboratories, Burlingame, CA, USA). To study Tau pathology and gliosis, stereological analyses were performed on about five sections of the hippocampus (400 µm intervals between sections). ImageJ (http://rsbweb.nih.gov/ij/) was set up to automatically detect the staining above a determined threshold.
Morris water maze
Mice were tested at 9 months as previously described (13) . Animal displacements were video tracked using Smart Junior software (Panlab ® , Cornellà, Spain).
Y maze
While most of our experiments were performed at 9 months of age, our recent observations (unpublished) indicated that THYTau22 mice were already severely impacted in the short-term memory Y-maze task at the age of 6 months. To confirm the data obtained using MWM at an earlier time-point, we thus used the short-term memory Y-maze task in another batch of WT and THY-Tau22 animals injected at 3.5 months of age. Mice were thus tested at 6 months with a protocol similar to that described previously (32) . The distance traveled and the number of entries into each arm were measured using ANY-maze software (Stoelting Co., Wood Dale, IL, USA). We also took the opportunity to use this behavioral task to perform our activation experiments for IEG analysis as stated below.
Microarrays
To activate IEG expression (64), mice were sacrificed 30 min after the Y maze task. Total RNA was obtained from frozen individual hippocampi and analyzed on DNA microarrays as previously described (64) .
Ex vivo electrophysiology
Electrophysiological experiments were performed with 9-monthold mice. Previously described methods were used for generation of hippocampal sections, recordings of presynaptic fiber volleys Dendrite and spine analysis (66) Morphological alterations in neuronal dendrites and dendritic spines were evaluated on 100-µm-thick sections stained as recommended with the FD Rapid GolgiStain™ Kit (FD NeuroTechnologies, Inc., Colombia, MD). Images were acquired as previously described (66) . Briefly, 5-8 slices per animal were imaged and 30-40 dendrites were measured per field of view to determine the average dendrite length; the frequencies of short (<20 µm), medium (>20-50 µm) and long (>50 µm) branches were calculated in a blind manner. Average dendrite length and spine density were analyzed using ImageJ software (NIH).
Statistical analyses
Statistical analyses were appropriate for the experimental design used. Outliers were detected and rejected using maximum normed residual test (Grubbs' test). In most cases, an ANOVA with Fisher's post hoc comparisons was used. Analysis of variance with repeated measures was used when required to assess complementary statistical effects. Student's t-tests were used for some experiments. Statistical significance was set to a P-value < 0.05 for all tests. Statistica (StatSoft ® , Inc., Tulsa, OK, USA) or GraphPad Prism ® (GraphPad Software, La Jolla, CA, USA) software were used.
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Supplementary Material is available at HMG online.
